Opendata, web and dolomites

IMMUNOTRAP SIGNED

Diagnosis test for immuno-oncology therapies.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUNOTRAP project word cloud

Explore the words cloud of the IMMUNOTRAP project. It provides you a very rough idea of what is the project "IMMUNOTRAP" about.

solution    physical    transfer    opportunity    intellectual    thanks    tumors    1980s    recognition    ground    endpoint    offers    light    oncology    characterization    successful    industry    exhibit    unmet    therapies    uses    disrupting    ago    efforts    innovation    boost    resonance    heterogeneity    assessing    forces    flow    receptors    diagnosis    market    cell    entry    differently    mutations    selecting    immunotherapies    awarded    drugs    pharmaceutical    suitable    immune    force    homogeneous    start    patient    measured    prize    cancers    immunoassays    clinical    efficient    mechanically    nobel    cells    precisely    transferring    cytometry    cancer    screening    drifting    laser    routes    immunotrap    workhorse    commercial    techniques    breaking    father    marketing    fundamental    technique    interaction    interact    act    genetic    create    platform    personalised    contact    invention    2018    generally    tweezers    affinity    impetux    treatments    company    physics    performance    samples    inmuno    surface    confirm    few    back    plasmon    adoptive    until    binding    optical   

Project "IMMUNOTRAP" data sheet

The following table provides information about the project.

Coordinator
IMPETUX OPTICS SL 

Organization address
address: CALLE TRIAS I GIRO 15
city: BARCELONA
postcode: 8034
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPETUX OPTICS SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Cancers exhibit a large heterogeneity in terms of genetic mutations, so they respond differently to the same drugs. This is why oncology is rapidly drifting towards treatments with new disrupting personalised inmuno-oncology therapies based on adoptive T-cell transfer (ACT). These therapies aim at selecting the most efficient T cells against tumors and transferring them back to the patient. This kind of Immunoassays are generally carried out with endpoint measurements like Surface Plasmon Resonance or Flow Cytometry. However, these techniques do not allow assessing the binding process between the immune and the target cell, which represents a fundamental step of the recognition phase where large efforts against cancer focus. IMPETUX has developed a solution to address this unmet need. The characterization of this affinity will be achieved through the measurement of the interaction force between them with IMMUNOTRAP: a platform for cell screening based on IMPETUX‘s optical tweezers. This technology uses a highly-focused laser light to mechanically interact with the sample without physical contact. The recent 2018 Nobel Prize in Physics was awarded to the intellectual father of this technique for his ground-breaking invention in the 1980s. However, it was not until few years ago that forces could start being measured on non-homogeneous samples, such as cells, thanks to the technology developed by IMPETUX. The IMMUNOTRAP has the potential to become the workhorse in the screening of the best performance receptors for their use in immunotherapies and offers IMPETUX the opportunity to address a high-growth potential market: the pharmaceutical industry and clinical diagnosis. It represents, therefore, a key opportunity to boost the company’s growth. Thus, the objectives of the present innovation project is precisely to confirm the potential of the proposal to create value and to identify the most suitable marketing and commercial routes for a successful market entry.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOTRAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOTRAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More